<DOC>
	<DOC>NCT01324999</DOC>
	<brief_summary>This study is designed to assess the efficacy and safety of tadalafil in patients with Sarcoidosis Associated Pulmonary Hypertension. Hypothesis: Tadalafil is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis</brief_summary>
	<brief_title>Tadalafil for Sarcoidosis Associated Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Biopsy proven sarcoidosis Mean pulmonary artery pressure &gt; 25 mmHg at rest or greater than 30 mmHg with exercise by right heart catheterization within 1 year prior to entry into study Pulmonary capillary wedge pressure ≤ 15 mmHg PVR values ≥ 3.0 Woods units Forced vital capacity (FVC) &gt; 40% predicted Forced expiratory volume in 1 second (FEV1) &gt; 40% predicted WHO functional class II or III Stable sarcoidosis treatment regimen for three months prior to entry into study 6 minute walk distance between 150450 meters Stable dose of antihypertensive medications On no other medication to treat PAH (sildenafil, vardenafil, treprostinil, epoprostenol, iloprost, bosentan, ambrisentan) within one month prior to enrollment and during duration of the study Nonpregnant females Exercise limitation related to a noncardiopulmonary reason (e.g. arthritis) Severe systemic hypertension &gt; 170/95 Severe systemic hypotension &lt; 90/50 History of priapism Patients with congestive heart failure (left ventricular dysfunction) LVEF &lt; 45% by echocardiogram Anticipation by the investigator for escalation in sarcoidosis treatment during the course of the study Pulmonary hypertension related to etiology other than sarcoidosis (i.e. HIV, scleroderma, chronic thromboemboli) Use within 1 month of an sildenafil or vardenafil WHO functional class IV status Patients with severe other organ disease felt by investigators to impact on survival during the course of the study Subjects with liver function abnormalities (ALT or AST &gt; 3 times the upper limit of normal at screening or at baseline) or chronic liver disease Advanced kidney failure (GFR &lt; 30 ml/min at screening or at baseline) History of hypersensitivity reaction or adverse effect related to tadalafil Pregnant or lactating women Concomitant use of nitrates (any form) either regularly or intermittently Concomitant use of potent CYP3A inhibitors (eg, ritonavir, ketoconazole, itraconazole) Any additional contraindications and precautions specified in the package inserts for Tadalafil (Adcirca) not listed above</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Sarcoidosis Associated Pulmonary Hypertension</keyword>
</DOC>